Gelesis Announces Upcoming Attendance at Wolfe Research’s Annual Consumer Growth Conference
BOSTON–(BUSINESS WIRE)–Gelesis Holdings, Inc. (NYSE: GLS) (“Gelesis” or the “Company”), maker of Plenity for weight management, today announced that its chief operating and David Pass, Pharm.D., will be featured in a panel discussion at Wolfe Research’s Virtual Consumer Growth Conference.
To listen to the event live or to schedule a meeting, please contact your Wolfe representative.
Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis”) is a consumer-focused biotherapy company and maker of nature-inspired, FDA-cleared Plenity® to aid in weight management . Our non-systemic superabsorbent hydrogels, the first of their kind, are made entirely from naturally-derived building blocks. They are inspired by the composition and mechanical properties of raw vegetables, taken in capsules, and act locally in the digestive system, so that people are satisfied with smaller portions. Our portfolio includes Plenity® and potential therapies in development for patients with type 2 diabetes, non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) and functional constipation. For more information, visit gelesis.com or connect with us on Twitter @GelesisInc. Plenity® is indicated to aid in weight management in adults with overweight or obesity, body mass index (BMI) of 25-40 kg/m², when used in conjunction with diet and exercise.
Important safety information about Plenity
Patients who are pregnant or allergic to cellulose, citric acid, sodium stearyl fumarate, gelatin or titanium dioxide should not take Plenity.
To avoid an impact on drug absorption:
For all medicines that must be taken with food, take them after starting a meal.
For all medicines that must be taken without food (on an empty stomach), continue taking on an empty stomach or as recommended by your doctor.
The overall incidence of side effects with Plenity was no different from placebo. The most common side effects were diarrhea, a distended abdomen, infrequent bowel movements and flatulence.
Contact a doctor immediately if any problems arise. If you have a severe allergic reaction, severe abdominal pain or severe diarrhoea, stop using Plenity until you can tell your doctor.
Rx only. For safe and proper use of Plenity or for more information, talk to a healthcare professional, read the Patient Instructions for Use, or call 1-844-PLENITY.
Certain statements, estimates, targets and projections contained in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws. The words “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “could”, “plan”, ” possible”, “potential”, “predict”, “project”, “should”, “endeavour”, “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that the statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, therefore, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding the expectations, hopes, beliefs, intentions or strategies of Gelesis or its management team regarding the future. In addition, any statement that refers to guidance, projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to place undue reliance on forward-looking statements, and Gelesis undertakes no obligation and does not intend to update or revise such forward-looking statements, whether as a result of new information, future events or otherwise. Gelesis does not guarantee that the expectations set forth in this press release will be achieved. A variety of risks, uncertainties (some of which are beyond Gelesis’ control) or other factors could cause actual future results, performance or events to differ materially from those described herein. Some of the factors that could affect future results and performance include, but are not limited to, the factors discussed in the “Risk Factors” section of Gelesis’ most recent Annual Report on Form 10-K and in other documents filed by Gelesis with the Securities and Exchange Commission. These filings address other important risks and uncertainties that could cause actual results and events to differ materially from those contained in the forward-looking statements.